自从1959年Avery和Mead阐明新生儿肺透明膜病(HMD)是由于肺表面活性物质(Pulmonary Surfactant,PS)缺乏或无活性所致以来,人们就开始探索HMD的病因治疗,即用外源性PS治疗本病。1980年,Fujiwara等用牛肺PS加合成磷脂治疗10例HMD首次获得成功。此后,国外大量报道各种外源性PS治疗HMD,并得到肯定疗效,本文主要介绍PS在HMD的临床应用。 Since Avery and Mead clarified in 1959 that neonatal hyaline membrane disease (HMD) is due to a lack or inactivity of pulmonary surfactant (PS), people began to explore the etiological treatment of HMD by using exogenous PS treatment of the disease. In 1980, Fujiwara et al treated 10 cases of HMD with bovine lung PS plus phospholipids for the first time successfully. Since then, a large number of foreign reports of various exogenous PS treatment of HMD, and get a positive effect, this article describes the clinical application of PS in the HMD.